Terns Pharmaceuticals, Inc. Insider Trading

TERN

Last 12 months

Insiders sold $2.07M and bought nothing on the open market.

95% of the selling was scheduled in advance under 10b5-1 plans. Chief Executive Officer Amy L. Burroughs sold — on Jan 5, 33% of their stake, outside a plan. The last open-market buy by an executive or director was in Jun 2025.

Net open-market

−$2.07M

0 buys · 7 sales

Under a 10b5-1 plan

95%

of the value sold

Insiders who bought / sold

0 / 3

executives and directors

Last open-market buy

Jun 2025

Jun 27, 2025

Get an email when TERN's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Apr 1	Emil Kuriakose Chief Medical Officer	SoldNo plan	942	$52.75	50K	0.9%	Form 4
Mar 16	Amy L. Burroughs Chief Executive Officer	Sold10b5-1 plan 2 parts	14,583	$46.71 average	681K	4.7%	Form 4
Feb 17	Amy L. Burroughs Chief Executive Officer	Sold10b5-1 plan 3 parts	14,583	$39.20 average	572K	4.7%	Form 4
Jan 15	Amy L. Burroughs Chief Executive Officer	Sold10b5-1 plan 2 parts	68,749	$37.53 average	282K	19%	Form 4
Jan 5	Amy L. Burroughs Chief Executive Officer	SoldNo plan	71,339	—	—	33%	Form 4
Jan 2	Emil Kuriakose Chief Medical Officer	SoldNo plan 2 parts	1,155	$38.57 average	45K	2.2%	Form 4
Nov 4, 2025	Jill M. Quigley Director	Sold10b5-1 plan	24,520	$18.00	441K	100%	Form 4
Oct 1, 2025	Emil Kuriakose Chief Medical Officer	SoldNo plan	944	$7.85	7K	1.8%	Form 4
Jul 1, 2025	Emil Kuriakose Chief Medical Officer	SoldNo plan	853	$4.27	4K	1.6%	Form 4
Jun 27, 2025	Andrew Gengos Chief Financial Officer	Bought 2 parts	10,000	$3.93 average	39K	67%	Form 4
Jun 25, 2025	Amy L. Burroughs Chief Executive Officer	Bought	23,314	$3.87	90K	98%	Form 4
Jun 13, 2025 – Jun 16, 2025	Andrew Gengos Chief Financial Officer	Bought 3 parts	15,000	$3.81 average	57K	New	Form 4
Apr 1, 2025	Emil Kuriakose Chief Medical Officer	SoldNo plan	952	$2.49	2K	1.8%	Form 4
Jan 2, 2025 – Jan 6, 2025	Mark J. Vignola Chief Financial Officer	Sold10b5-1 plan 2 parts	17,188	$5.76 average	99K	19%	Form 4
Jan 2, 2025 – Jan 6, 2025	Jill M. Quigley Director	Sold10b5-1 plan 2 parts	15,000	$5.76 average	86K	100%	Form 4
Jan 2, 2025	Emil Kuriakose Chief Medical Officer	SoldNo plan	4,481	$5.71	26K	7.6%	Form 4
Dec 5, 2024	Amy L. Burroughs Chief Executive Officer	Bought	15,450	$7.15	110K	423%	Form 4
Nov 30, 2024	Melita Sun Jung Chief Business Officer	Bought	2,250	$5.11	11K	New	Form 4
Nov 30, 2024	Amy L. Burroughs Chief Executive Officer	Bought	510	$5.11	3K	2.7%	Form 4

Apr 1No plan
Emil Kuriakose
Chief Medical Officer · sold 942 at $52.75
50K
0.9% of stake
Mar 1610b5-1 plan
Amy L. Burroughs
Chief Executive Officer · sold 14,583 at avg $46.71
681K
4.7% of stake
Feb 1710b5-1 plan
Amy L. Burroughs
Chief Executive Officer · sold 14,583 at avg $39.20
572K
4.7% of stake
Jan 1510b5-1 plan
Amy L. Burroughs
Chief Executive Officer · sold 68,749 at avg $37.53
282K
19% of stake
Jan 5No plan
Amy L. Burroughs
Chief Executive Officer · sold 71,339
—
33% of stake
Jan 2No plan
Emil Kuriakose
Chief Medical Officer · sold 1,155 at avg $38.57
45K
2.2% of stake
Nov 4, 202510b5-1 plan
Jill M. Quigley
Director · sold 24,520 at $18.00
441K
100% of stake
Oct 1, 2025No plan
Emil Kuriakose
Chief Medical Officer · sold 944 at $7.85
7K
1.8% of stake
Jul 1, 2025No plan
Emil Kuriakose
Chief Medical Officer · sold 853 at $4.27
4K
1.6% of stake
Jun 27, 2025
Andrew Gengos
Chief Financial Officer · bought 10,000 at avg $3.93
39K
67% of stake
Jun 25, 2025
Amy L. Burroughs
Chief Executive Officer · bought 23,314 at $3.87
90K
98% of stake
Jun 13, 2025 – Jun 16, 2025
Andrew Gengos
Chief Financial Officer · bought 15,000 at avg $3.81
57K
New position
Apr 1, 2025No plan
Emil Kuriakose
Chief Medical Officer · sold 952 at $2.49
2K
1.8% of stake
Jan 2, 2025 – Jan 6, 202510b5-1 plan
Mark J. Vignola
Chief Financial Officer · sold 17,188 at avg $5.76
99K
19% of stake
Jan 2, 2025 – Jan 6, 202510b5-1 plan
Jill M. Quigley
Director · sold 15,000 at avg $5.76
86K
100% of stake
Jan 2, 2025No plan
Emil Kuriakose
Chief Medical Officer · sold 4,481 at $5.71
26K
7.6% of stake
Dec 5, 2024
Amy L. Burroughs
Chief Executive Officer · bought 15,450 at $7.15
110K
423% of stake
Nov 30, 2024
Melita Sun Jung
Chief Business Officer · bought 2,250 at $5.11
11K
New position
Nov 30, 2024
Amy L. Burroughs
Chief Executive Officer · bought 510 at $5.11
3K
2.7% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch TERN, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with TERN

CompareIntrinsic value

STTKShattuck Labs Inc.

$5.56-2.80%40

RFLRafael Holdings Inc.

$1.08-3.57%40

ORGSOrgenesis Inc.

$0.05+0.00%20

IGCIGC Pharma Inc.

$0.19-5.00%26

SXTP60 Degrees Pharmaceuticals Inc.

$0.94-0.84%40

NEUPNeuphoria Therapeutics Inc.

$3.05-0.33%10

SCNXScienture Holdings Inc.

$3.22-7.74%0

LGVNLongeveron Inc.

$1.67-4.57%10

Spot a number that looks wrong? Check it in TERN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing TERN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.